Cargando…

Nitric Oxide Synthesis Is Reduced in Subjects With Type 2 Diabetes and Nephropathy

OBJECTIVE: Nitric oxide (NO) is a key metabolic and vascular regulator. Its production is stimulated by insulin. A reduced urinary excretion of NO products (NOx) is frequently found in type 2 diabetes, particularly in association with nephropathy. However, whether the decreased NOx excretion in type...

Descripción completa

Detalles Bibliográficos
Autores principales: Tessari, Paolo, Cecchet, Diego, Cosma, Alessandra, Vettore, Monica, Coracina, Anna, Millioni, Renato, Iori, Elisabetta, Puricelli, Lucia, Avogaro, Angelo, Vedovato, Monica
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2927936/
https://www.ncbi.nlm.nih.gov/pubmed/20484137
http://dx.doi.org/10.2337/db09-1772
_version_ 1782185802448502784
author Tessari, Paolo
Cecchet, Diego
Cosma, Alessandra
Vettore, Monica
Coracina, Anna
Millioni, Renato
Iori, Elisabetta
Puricelli, Lucia
Avogaro, Angelo
Vedovato, Monica
author_facet Tessari, Paolo
Cecchet, Diego
Cosma, Alessandra
Vettore, Monica
Coracina, Anna
Millioni, Renato
Iori, Elisabetta
Puricelli, Lucia
Avogaro, Angelo
Vedovato, Monica
author_sort Tessari, Paolo
collection PubMed
description OBJECTIVE: Nitric oxide (NO) is a key metabolic and vascular regulator. Its production is stimulated by insulin. A reduced urinary excretion of NO products (NOx) is frequently found in type 2 diabetes, particularly in association with nephropathy. However, whether the decreased NOx excretion in type 2 diabetes is caused by a defective NOx production from arginine in response to hyperinsulinemia has never been studied. RESEARCH DESIGN AND METHODS: We measured NOx fractional (FSR) and absolute (ASR) synthesis rates in type 2 diabetic patients with diabetic nephropathy and in control subjects, after l-[(15)N(2)-guanidino]-arginine infusion, and use of precursor–product relationships. The study was conducted both before and after an euglycemic hyperinsulinemic (∼1,000–1,200 pmol/l) clamp. RESULTS: In type 2 diabetes, NOx FSR was reduced both under basal (19.3 ± 3.9% per day, vs. 22.9 ± 4.5% per day in control subjects) and hyperinsulinemic states (24.0 ± 5.6% per day, vs. 37.9 ± 6.4% per day in control subjects; P < 0.03 by ANOVA). Similarly, in type 2 diabetes, NOx ASR was lower than in control subjects under both conditions (basal, 0.32 ± 0.06 vs. 0.89 ± 0.34 mol per day; hyperinsulinemia, 0.35 ± 0.07 vs. 1.15 ± 0.38 mol per day; P = 0.01 by ANOVA). In type 2 diabetes, the ability of insulin to stimulate both the FSR (4.7 ± 3.2% per day) and the ASR (0.03 ± 0.04 mol per day) of NOx was several-fold lower than that in control subjects (15.0 ± 2.9% per day and 0.25 ± 0.07 mol per day, P < 0.03 and P < 0.02, respectively). Also the fraction of arginine flux converted to NOx (basal, 0.22 ± 0.05% vs. 0.65 ± 0.25%; hyperinsulinemia, 0.32 ± 0.06% vs. 1.03 ± 0.33%) was sharply reduced in the patients (P < 0.01 by ANOVA). CONCLUSIONS: In type 2 diabetic patients with nephropathy, intravascular NOx synthesis from arginine is decreased under both basal and hyperinsulinemic states. This defect extends the concept of insulin resistance to NO metabolism.
format Text
id pubmed-2927936
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-29279362011-09-01 Nitric Oxide Synthesis Is Reduced in Subjects With Type 2 Diabetes and Nephropathy Tessari, Paolo Cecchet, Diego Cosma, Alessandra Vettore, Monica Coracina, Anna Millioni, Renato Iori, Elisabetta Puricelli, Lucia Avogaro, Angelo Vedovato, Monica Diabetes Metabolism OBJECTIVE: Nitric oxide (NO) is a key metabolic and vascular regulator. Its production is stimulated by insulin. A reduced urinary excretion of NO products (NOx) is frequently found in type 2 diabetes, particularly in association with nephropathy. However, whether the decreased NOx excretion in type 2 diabetes is caused by a defective NOx production from arginine in response to hyperinsulinemia has never been studied. RESEARCH DESIGN AND METHODS: We measured NOx fractional (FSR) and absolute (ASR) synthesis rates in type 2 diabetic patients with diabetic nephropathy and in control subjects, after l-[(15)N(2)-guanidino]-arginine infusion, and use of precursor–product relationships. The study was conducted both before and after an euglycemic hyperinsulinemic (∼1,000–1,200 pmol/l) clamp. RESULTS: In type 2 diabetes, NOx FSR was reduced both under basal (19.3 ± 3.9% per day, vs. 22.9 ± 4.5% per day in control subjects) and hyperinsulinemic states (24.0 ± 5.6% per day, vs. 37.9 ± 6.4% per day in control subjects; P < 0.03 by ANOVA). Similarly, in type 2 diabetes, NOx ASR was lower than in control subjects under both conditions (basal, 0.32 ± 0.06 vs. 0.89 ± 0.34 mol per day; hyperinsulinemia, 0.35 ± 0.07 vs. 1.15 ± 0.38 mol per day; P = 0.01 by ANOVA). In type 2 diabetes, the ability of insulin to stimulate both the FSR (4.7 ± 3.2% per day) and the ASR (0.03 ± 0.04 mol per day) of NOx was several-fold lower than that in control subjects (15.0 ± 2.9% per day and 0.25 ± 0.07 mol per day, P < 0.03 and P < 0.02, respectively). Also the fraction of arginine flux converted to NOx (basal, 0.22 ± 0.05% vs. 0.65 ± 0.25%; hyperinsulinemia, 0.32 ± 0.06% vs. 1.03 ± 0.33%) was sharply reduced in the patients (P < 0.01 by ANOVA). CONCLUSIONS: In type 2 diabetic patients with nephropathy, intravascular NOx synthesis from arginine is decreased under both basal and hyperinsulinemic states. This defect extends the concept of insulin resistance to NO metabolism. American Diabetes Association 2010-09 2010-05-18 /pmc/articles/PMC2927936/ /pubmed/20484137 http://dx.doi.org/10.2337/db09-1772 Text en © 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Metabolism
Tessari, Paolo
Cecchet, Diego
Cosma, Alessandra
Vettore, Monica
Coracina, Anna
Millioni, Renato
Iori, Elisabetta
Puricelli, Lucia
Avogaro, Angelo
Vedovato, Monica
Nitric Oxide Synthesis Is Reduced in Subjects With Type 2 Diabetes and Nephropathy
title Nitric Oxide Synthesis Is Reduced in Subjects With Type 2 Diabetes and Nephropathy
title_full Nitric Oxide Synthesis Is Reduced in Subjects With Type 2 Diabetes and Nephropathy
title_fullStr Nitric Oxide Synthesis Is Reduced in Subjects With Type 2 Diabetes and Nephropathy
title_full_unstemmed Nitric Oxide Synthesis Is Reduced in Subjects With Type 2 Diabetes and Nephropathy
title_short Nitric Oxide Synthesis Is Reduced in Subjects With Type 2 Diabetes and Nephropathy
title_sort nitric oxide synthesis is reduced in subjects with type 2 diabetes and nephropathy
topic Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2927936/
https://www.ncbi.nlm.nih.gov/pubmed/20484137
http://dx.doi.org/10.2337/db09-1772
work_keys_str_mv AT tessaripaolo nitricoxidesynthesisisreducedinsubjectswithtype2diabetesandnephropathy
AT cecchetdiego nitricoxidesynthesisisreducedinsubjectswithtype2diabetesandnephropathy
AT cosmaalessandra nitricoxidesynthesisisreducedinsubjectswithtype2diabetesandnephropathy
AT vettoremonica nitricoxidesynthesisisreducedinsubjectswithtype2diabetesandnephropathy
AT coracinaanna nitricoxidesynthesisisreducedinsubjectswithtype2diabetesandnephropathy
AT millionirenato nitricoxidesynthesisisreducedinsubjectswithtype2diabetesandnephropathy
AT iorielisabetta nitricoxidesynthesisisreducedinsubjectswithtype2diabetesandnephropathy
AT puricellilucia nitricoxidesynthesisisreducedinsubjectswithtype2diabetesandnephropathy
AT avogaroangelo nitricoxidesynthesisisreducedinsubjectswithtype2diabetesandnephropathy
AT vedovatomonica nitricoxidesynthesisisreducedinsubjectswithtype2diabetesandnephropathy